Coffee review

Coffee May Lower Risk of Prostate Cancer

Published: 2025-08-21 Author: World Gafei
Last Updated: 2025/08/21, Three or more cups of coffee a day may reduce the risk of prostate cancer, a new study suggests. The anti-tumor effect of coffee has also been confirmed by laboratory experiments. Meta-analysis data on the effect of coffee on prostate cancer risk are controversial. Caffeine as a bioactive compound in coffee has not been studied in vitro. The study was designed to assess the effects of Italian coffee on patients with prostate cancer

Three or more cups of coffee a day can reduce the risk of prostate cancer, according to a new study. The anti-tumor effect of coffee was also confirmed by laboratory experiments.

Meta analysis data on the effect of coffee on the risk of prostate cancer are controversial. Caffeine as a bioactive compound of coffee has not been deeply studied in vitro. The purpose of this study was to assess the effect of Italian coffee on the risk of prostate cancer and to study the potential anti-proliferation and anti-metastasis activity of caffeine on prostate cancer cell lines in vitro.

In the Moli-sani group, 6989 men aged 50 or older were followed up for an average of 4.24 ±1.35 years, and 100 new cases of prostate cancer were identified. A questionnaire on cancer and nutrition-food frequency questionnaires was carried out in Europe, which is used to assess diet and Italian coffee consumption. Two human prostate cancer cell lines PC-3 and DU145 were tested with increased concentration of caffeine and their proliferation / metastasis characteristics were evaluated. Compared with the non-patient group (74.0 ±51.7 g / d), the newly diagnosed prostate cancer patients who reduced coffee consumption (60.1 ±51.3 g / d) (p 3 cups / day) reduced their prostate cancer risk by 53% (p = 0.02). A significant decrease in proliferation and metastatic behavior of human prostate cancer cell lines treated with caffeine (p 3 cups per day) can reduce the risk of prostate cancer. Caffeine has anti-proliferation and anti-metastasis activities on two prostate cancer cell lines PC-3 and DU145, thus providing cell confirmation for the results of the cohort study.

0